Want to see DYAI full AI Analyst Report?
DYAI Stock Chart & Stats
$0.66
-$0.06(-5.04%)
At close: 4:00 PM EDT
$0.66
-$0.06(-5.04%)
Day’s Range― - ―
52-Week Range$0.34 - $1.60
Previous Close$1.13
Volume112.54K
Average Volume (3M)173.34K
Market Cap
$15.26M
Enterprise Value$33.03M
Total Cash (Recent Filing)$3.11M
Total Debt (Recent Filing)$5.05M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding40,063,700
10 Day Avg. Volume118,404
30 Day Avg. Volume173,344
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)24.88
Price to Sales (P/S)24.89
P/FCF Ratio-5.38
Enterprise Value/Market Cap2.16
Enterprise Value/Revenue9.51
Enterprise Value/Gross Profit31.24
Enterprise Value/Ebitda-4.60
Forecast
1Y Price Target
$4.00Price Target Upside506.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$6.61M
Bulls Say, Bears Say
Bulls Say
Platform Productivity ImprovementThe transferrin productivity gain indicates that Dyadic’s platform can improve output economics at pilot scale. If replicated commercially, lower manufacturing costs could strengthen customer adoption, support partner returns, and improve the competitiveness of C1-produced biologics over the next several quarters.
Early Revenue And Commercialization GrowthThe year-to-date revenue increase reflects progress beyond laboratory development toward grants, product shipments, and early commercial activity. Continued conversion of qualification work and distribution relationships into orders could broaden revenue sources and provide evidence that the platform is gaining market traction.
Externally Funded Platform ValidationExternal funding helps validate the C1 platform in biopharma applications while reducing the amount of internal capital required for selected development programs. The demonstrated 15-day plasmid-to-protein workflow also supports differentiated speed for partners pursuing vaccines and other biologics.
Bears Say
Persistent Losses And Cash BurnSustained negative operating and free cash flow shows that Dyadic is not yet self-funding its operations. Continued cash consumption limits investment flexibility and means future commercialization, research, and corporate expenses depend on additional financing or successful external funding.
Negative Equity And Elevated Balance-sheet RiskThe equity deficit indicates that accumulated losses have eroded the company’s capital base, while debt remains material relative to assets. This weak financial position can constrain strategic flexibility and increase pressure to raise capital before the business reaches sustainable profitability.
Going-concern And Financing DependenceThe going-concern disclosure makes financing execution a central business risk rather than a peripheral concern. With limited cash relative to ongoing losses, delays in licensing, milestones, grants, partnerships, or other financing could restrict operations and slow commercialization.
Dyadic International News
DYAI FAQ
What was Dyadic International’s price range in the past 12 months?
Dyadic International lowest stock price was $0.34 and its highest was $1.60 in the past 12 months.
What is Dyadic International’s market cap?
Dyadic International’s market cap is $15.26M.
When is Dyadic International’s upcoming earnings report date?
Dyadic International’s upcoming earnings report date is Nov 11, 2026 which is in 20 days.
How were Dyadic International’s earnings last quarter?
Dyadic International released its earnings results on Aug 12, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.035 by -$0.025.
Is Dyadic International overvalued?
According to Wall Street analysts Dyadic International’s price is currently Undervalued.
Does Dyadic International pay dividends?
Dyadic International does not currently pay dividends.
What is Dyadic International’s EPS estimate?
Dyadic International’s EPS estimate is -0.05.
How many shares outstanding does Dyadic International have?
Dyadic International has 40,063,700 shares outstanding.
What happened to Dyadic International’s price movement after its last earnings report?
Dyadic International reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.035. Following the earnings report the stock price went down -16.19%.
Which hedge fund is a major shareholder of Dyadic International?
Currently, no hedge funds are holding shares in DYAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dyadic International
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
DYAI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents meaningful operational and technical progress—notably an 80% productivity improvement for transferrin, a 15-day plasmid-to-protein capability, growing product shipments and partner commercialization, and a 52% year-to-date revenue increase—indicating positive momentum in commercialization and platform validation. However, financial performance and liquidity pose near-term risks: Q2 revenue was flat year-over-year, cost of revenue rose 60% and exceeded revenue for the quarter, operating and net losses persist, G&A increased, and management disclosed substantial doubt about going concern with only ~$4.8M in cash. Management is pursuing non-dilutive and strategic financing and emphasizing capital-efficient commercialization, but the business remains early-stage and cash-constrained. Overall, progress is encouraging on the technical and commercial fronts, but financial and execution risks keep the outlook balanced.View all DYAI earnings summariesDYAI Stock 12 Month Forecast
Average Price Target
$4.00
▲(506.06% Upside)
Technical Analysis
Ownership Overview
22.17% Insiders
2.96% Mutual Funds
2.43% Other Institutional Investors
70.13% Public Companies and
Individual Investors